BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 "引人入胜

Reuters09-16

((自动化翻译由路透提供，请见免责声明 ))

9月16日 - ** 券商Guggenheim指出，辉瑞公司的ponsegromab治疗癌症恶病质的中期数据 "引人入胜"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。

** PFE 在欧洲肿瘤内科学会(ESMO) 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。

** 券商继续看好强生公司的TAR-200治疗非肌浸润性膀胱癌的数据，该药有望在2025年提交监管申请

** 称默克的Keytruda的最新数据显示，它将继续重新定义各种肿瘤类型的治疗标准；并称预计百时美施贵宝的肺癌数据更新影响不大

** 艾伯维的ESMO "相对平静"，但券商注意到抗体药物共轭物（一类被称为 "制导导弹 "的抗癌药物）的持续开发

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2467061816?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-16 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467061816","market":"us","top_or_hot":-1,"title":"BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 \"引人入胜","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    9月16日 - ** 券商Guggenheim指出，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>公司  的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。</p><p>** PFE 在欧洲肿瘤内科学会(ESMO) 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。</p><p>** 券商继续看好<a href=\"https://laohu8.com/S/JNJ\">强生</a>公司  的TAR-200治疗非肌浸润性膀胱癌的数据，该药有望在2025年提交监管申请</p><p>** 称默克  的Keytruda的最新数据显示，它将继续重新定义各种肿瘤类型的治疗标准；并称预计百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a>  的肺癌数据更新影响不大</p><p>** 艾伯维  的ESMO \"相对平静\"，但券商注意到抗体药物共轭物（一类被称为 \"制导导弹 \"的抗癌药物）的持续开发 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 \"引人入胜</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 \"引人入胜\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 19:15 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    9月16日 - ** 券商Guggenheim指出，辉瑞公司  的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。** PFE 在欧洲肿瘤内科学会(ESMO) 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。** 券商继续看好强生...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1196500208.SGD","symbol_name":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2467061816","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467061816","pubTimestamp":1726485344,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    9月16日 - ** 券商Guggenheim指出，辉瑞公司  的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。** PFE 在欧洲肿瘤内科学会 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4504":"桥水持仓","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","PFE":"辉瑞","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4592":"伊斯兰概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","MRK":"默沙东","ABBV":"艾伯维公司","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4139":"生物科技","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","JNJ":"强生","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","BMY":"施贵宝","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC"},"translate_title":"BUZZ-Guggenheim calls Pfizer's mid-term anticancer drug data released at ESMO \"fascinating\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"MRK":0.9,"ABBV":0.9,"BMY":0.9,"JNJ":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    9月16日 - ** 券商Guggenheim指出，辉瑞公司  的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。** PFE 在欧洲肿瘤内科学会(ESMO) 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。** 券商继续看好强生公司  的TAR-200治疗非肌浸润性膀胱癌的数据，该药有望在2025年提交监管申请** 称默克  的Keytruda的最新数据显示，它将继续重新定义各种肿瘤类型的治疗标准；并称预计百时美施贵宝  的肺癌数据更新影响不大** 艾伯维  的ESMO \"相对平静\"，但券商注意到抗体药物共轭物（一类被称为 \"制导导弹 \"的抗癌药物）的持续开发","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467061816"}